CMD 011
Alternative Names: CMD-011Latest Information Update: 28 Jul 2026
At a glance
- Originator Zhejiang Shimai Pharmaceutical
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I/II Liver cancer
Most Recent Events
- 28 Jul 2026 No recent reports of development identified for preclinical development in Liver-cancer in USA (IV, Injection)
- 19 Sep 2025 CMD 011 is available for licensing as of 19 Sep 2025. https://www.centrymed.com/science-pip (Zhejiang Shimai Pharmaceutical pipeline, September 2025)
- 21 Feb 2025 The US FDA approves IND application for CMD 011 in Liver cancer